Monday, October 15, 2018

Allele Biotech Gets NIH Grant

San Diego-based Alle Biotechnology reported this morning that it has received a Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences of NIH. Size of the grant was not announced. According to Allele, the grant covers the development of new single-domain nanoantibody (nAb) therapies for the treatment of sepsis. According to Allele, sepsis and septic shock are among the leading causes of death in intensive care units (ICUs). Allele's treatments for sepsis revolve around managing the intense inflammatory response associated with the condition, involving "multi-valent and multi-specific nAbs" which were recently identified from an immunized llama.